Showing 2971-2980 of 7016 results for "".
Avoiding Complications in Surgical and Nonsurgical Aesthetics
https://reachmd.com/topics/surgical/avoiding-complications-in-surgical-and-nonsurgical-aesthetics/48892/Improving Sleep and Mental Health in Patients with CKD-aP
https://reachmd.com/programs/cme/improving-sleep-and-mental-health-in-patients-with-ckd-ap/36301/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Delaying Rheumatoid Arthritis with Abatacept: ARIAA Trial Findings
https://reachmd.com/programs/living-rheum/delaying-rheumatoid-arthritis-with-abatacept-ariaa-trial-findings/32799/DOR/ISL Two-Drug Regimen for HIV-1 Is Non-Inferior to BIC/FTC/TAF
https://reachmd.com/programs/clinicians-roundtable/dorisl-two-drug-regimen-for-hiv-1-is-non-inferior-to-bicftctaf/32856/STORM-PE: Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism
https://reachmd.com/programs/clinicians-roundtable/storm-pe-mechanical-thrombectomy-in-intermediate-high-risk-pulmonary-embolism/35663/Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
https://reachmd.com/programs/vaccination/evaluating-menb-vaccines-beyond-the-traditional-hsba-assay/37106/Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
https://reachmd.com/programs/project-oncology/mutational-complexity-in-ros1-positive-mnsclc-insights-from-real-world-practice/36564/Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
https://reachmd.com/programs/neurofrontiers/program-name/36353/Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
https://reachmd.com/programs/cme/incorporating-guideline-recommended-targeted-therapies-into-rr-aml-management/36181/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Balancing Benefits and Risks in Emerging Sickle Cell Therapies
https://reachmd.com/programs/project-oncology/balancing-benefits-and-risks-in-emerging-sickle-cell-therapies/36236/For decades, hydroxyurea has been the cornerstone therapy for sickle cell disease, but new disease-modifying therapies, curative strategies, and gene therapies are expanding options for patients. While these advancing approaches come with some risks, they can help offer symptom relief, reduce compli